NCT06322108 - Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Botensilimab + Balstilimab

Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).

Trial Locations (1)

0014

RECRUITING

Hematology Center named after prof. R. Yeolyan, Yerevan